Matt Phipps gives his take on biotech and discusses #ATS2024 data, Amgen and Keros' obesity programs, recent acquisitions by GenMab and...

Doug Edgeton describes the growth that has taken place since North Carolina Biotechnology Center was founded four decades ago, and what...

Laura Niklason shows us what Humacyte's Human Acellular Vessel (HAV) looks like, describes how it is manufactured, explains its utility,...

Joining us from their lab space in Raleigh, Executive Director Josh Sommer and CSO Dan Freed introduce us to chordoma and describe the...

Hatteras Venture Partners' Clay Thorp describes the growth of North Carolina's biotech industry during his firm's 20+ years of...

CEO Jon Stonehouse describes how making it across the finish line with Orladeyo has put BioCryst in a position after may decades of drug...

Martin Lehr describes how Nextech enabled this private placement that may allow the company to accelerate clinical development to...

CEO Faheem Hasnian and trial investigator Olivier Sitbon describe how some patients seem to not just be maintaining benefit, but...

John Hood describes how the 12 week data Endeavor is witnessing is giving the company optimism that it might be reversing, rather than...

Dean of Biomedical Studies Kristy Shuda McGuire describes how the BTT program trains community college and other students in lab work,...

Leah Fung describes how Biotheryx is leveraging the E3 ligase Cereblon to enable its protein degradation, and discusses the lead CD4/6...

Chris McCarthy describes how investors are anticipating upcoming binary events and how they have been talking about broader market issues.

Roberto Bellini introduces us to his new investment firm and looks back on lessons learned from selling BELLUS to GSK.

Noël Brown shares his thoughts on the IPO market and its pipeline, following-on offerings, and takaways from the RBC Capital Markets...

Dr. Matthew Klein provides updates on Translarna, Sepiapterin, Vatiquinone, Utreloxastat, PTC518, and more.

Bernard Coulie gives a deep dive into Pliant's IPF program, including news released this morning relating to patient PET scans.

Ian Mortimer gives the rationale for Kv7 in epilepsy and major depressive disorder, and explains why Xenon has chosen the NaV1.7 sodium...

Yuval Cohen describes why he believe his company's nectin-4 ADC has a next generation design, he covers the idea of integrin inhibition...

Brian Abrahams previews the conference, shares his take on biotech, and offers some themes to watch throughout the remainder of the year.

Thomas Renn, Head of Europe for Breakthrough Properties, introduces us to this state-of-the-art facility that will encompass 214,000...